Skip to main content

Loading market data...

PRCT

PROCEPT BioRobotics Corporation

NASDAQ • United states

$18.27

-$0.55

(-2.92%)

Source: Yahoo Finance · Quote time Oct 21, 2026 20:00 GMT+0000

Catalyst Evidence

No verified catalyst stored yet

Click “View” to see the stored chain of evidence (if available).

Management
Credibility
Score

PROCEPT BioRobotics Corporation (PRCT)

Unavailable

Quotes may be delayed

$1.05B

Market Cap

733,160

Volume

Unavailable

P/E Ratio

Unavailable

Div Yield

PROCEPT BioRobotics Corporation Price Chart

Loading price history…

Management Credibility Analysis

Unavailable

Verified Management Score Unavailable

Management credibility requires sourced guidance and earnings history.

Upcoming Catalysts

Verified event feed

Verified Catalysts Unavailable

No sourced upcoming event feed is configured for this stock yet.

Company profile

No description available

Chief executive: Not disclosed
Headquarters: 150 BAYTECH DRIVE, SAN JOSE, CA
Founded: Not disclosed

📈 Company Timeline

Major business events

Positive

Negative

Neutral

3 Oct 2026

PROCEPT BioRobotics Corporation reported A director or senior management change or compensation event

PROCEPT BioRobotics Corporation filed an 8-K covering a director or senior management change or compensation event, supporting financial statements or exhibits.

25 Sep 2026

PROCEPT BioRobotics Corporation reported A material agreement

PROCEPT BioRobotics Corporation filed an 8-K covering a material agreement, supporting financial statements or exhibits.

6 Aug 2026

PROCEPT BioRobotics Corporation filed Form 10-Q

PROCEPT BioRobotics Corporation submitted Form 10-Q to the SEC for the period ending Jun 30, 2026.

5 Aug 2026

PROCEPT BioRobotics Corporation reported Operating or financial results

PROCEPT BioRobotics Corporation filed an 8-K covering operating or financial results, supporting financial statements or exhibits.

29 Jul 2026

Large-holder ownership filing

A holder reported or amended a beneficial ownership position of more than 5% in PROCEPT BioRobotics Corporation.

Capital Structure & Financial Position

Financial strength and liquidity analysis

Cash and equivalents (USD)$227.91M

Total assets (USD)$479.35M

Total liabilities (USD)$139.28M

Shareholders' equity (USD)$340.07M

Long-term debt (USD)$51.72M

Debt due within a year (USD)$0

Source: SEC EDGAR company facts (opens in a new tab) Balance sheet dated 30 Jun 2026

Peer Comparison - Health Care

Company	Price	Market Cap
LLY - Eli Lilly and Company	$1,276.13 Yahoo Finance	$1.20T
JNJ - Johnson & Johnson	$256.74 Yahoo Finance	$618.71B
ABBV - AbbVie Inc.	$284.80 Yahoo Finance	$503.28B
UNH - UnitedHealth Group Incorporated	$418.43 Yahoo Finance	$375.58B
MRK - Merck & Co., Inc.	$148.55 Yahoo Finance	$366.50B

📋 Corporate Actions

Recent and upcoming corporate events

Verified Corporate Actions Unavailable

Dividend, buyback, split, and spin-off feeds are not ingested for this stock yet.

Financials

Financial statements and key metrics analysis

Quarter	Revenue (USD)	Operating income	Net income	Diluted EPS (USD)	Filed
Q2 2026	$94.50M	−$27.39M	−$26.86M	−$0.47	10-Q · 5 Aug 2026
Q1 2026	$83.13M	−$32.61M	−$31.64M	−$0.56	10-Q · 30 Apr 2026
Q4 2025	$76.38M	−$31.04M	$65.63M	Unavailable	10-K · 26 Feb 2026
Q3 2025	$83.33M	−$23.19M	−$21.41M	−$0.38	10-Q · 5 Nov 2025
Q2 2025	$79.18M	−$22.19M	−$19.58M	−$0.35	10-Q · 7 Aug 2025
Q1 2025	$69.16M	−$27.44M	−$24.74M	−$0.45	10-Q · 2 May 2025

Source: SEC EDGAR company facts (opens in a new tab)

Analyst Consensus

Neutral

Target: $22.89

25.3% upside potential

📈

Strong Buy

Unavailable

👍

Buy

4

⏸️

Hold

7

📉

Sell

1

12 analysts covering this stock

Source: Nasdaq analyst research (opens in a new tab) Retrieved 22 Oct 2026, 05:50 UTC Targets range 19.00–30.00 Ratings are third-party opinions, not advice.

💰 Upcoming Dividends

Next dividend payments

Verified Dividend Data Unavailable

Dividend calendar data is not ingested for this stock yet.

Guidance Evolution

Verified Guidance History Unavailable

Verified company guidance history is not ingested for this stock yet.

💼 Director Transactions

Recent insider activity

2

Oct 2026

Mack Michael

Director

Grant or award

Unavailable per share

7,727 shares

9

Sep 2026

Nouri Alaleh

EVP, CLO, CORP. SEC.

Open-market sale

$20.95 per share

297 shares

9

Sep 2026

Templin Barry L

EVP, Chief Technology Officer

Open-market sale

$20.95 per share

373 shares

9

Sep 2026

Waters Kevin

EVP, CFO

Open-market sale

$20.95 per share

373 shares

13

Aug 2026

Nouri Alaleh

EVP, CLO, CORP. SEC.

Grant or award

Unavailable per share

22,965 shares

13

Aug 2026

Templin Barry L

EVP, Chief Technology Officer

Grant or award

Unavailable per share

26,246 shares

13

Aug 2026

Waters Kevin

EVP, CFO

Grant or award

Unavailable per share

29,527 shares

13

Aug 2026

Sharma Pooja

Chief Strat/Marketing Officer

Grant or award

Unavailable per share

23,622 shares

Top Shareholders

Vanguard Group Inc

5,202,306 shares

-0.06% change

12/31/2025

Blackrock, Inc.

4,869,828 shares

11.642% change

6/30/2026

T. Rowe Price Investment Management, Inc.

3,265,704 shares

-0.247% change

6/30/2026

Bnp Paribas Asset Management Holding S.A.

2,823,849 shares

-8.595% change

6/30/2026

Vanguard Portfolio Management Llc

2,526,802 shares

4.355% change

6/30/2026

Vanguard Capital Management Llc

2,460,802 shares

2.573% change

6/30/2026

State Street Corp

1,617,475 shares

5.743% change

6/30/2026

Geode Capital Management, Llc

1,484,163 shares

8.85% change

6/30/2026

Fmr Llc

1,444,878 shares

-1.165% change

6/30/2026

Price T Rowe Associates Inc /Md/

1,332,452 shares

119.892% change

6/30/2026

Source: Nasdaq institutional holdings (opens in a new tab) Observed 22 Oct 2026, 05:50 UTC· 1 hour ago

Research coverage and investment tools

PROCEPT BioRobotics Corporation (PRCT) is a stock listed on the Nasdaq in the United States, in the Health Care sector (Medical/Dental Instruments). Its last price was US$18.27 on 21 Oct 2026. That is 7% of the way from its 52-week low of US$16.67 to its 52-week high of US$38.11. Its market capitalisation was US$1.05 billion at that price.

Watch Add to portfolio Set an alert Compare Position size

How position sizing works Dividend yield and total return

Quarter	Revenue	Operating income	Net income	Diluted EPS	Gross margin	Operating margin	Free cash flow	Filed
Q2 2026	$94.50M	−$27.39M	−$26.86M	−$0.47	66.0%	-29.0%	−$22.20M	10-Q · 5 Aug 2026 (opens in a new tab)
Q1 2026	$83.13M	−$32.61M	−$31.64M	−$0.56	64.9%	-39.2%	−$41.04M	10-Q · 30 Apr 2026 (opens in a new tab)
Q4 2025	$76.38M	−$31.04M	$65.63M	Unavailable	60.6%	-40.6%	−$12.18M	10-K · 26 Feb 2026 (opens in a new tab)
Q3 2025	$83.33M	−$23.19M	−$21.41M	−$0.38	64.8%	-27.8%	−$9.50M	10-Q · 5 Nov 2025 (opens in a new tab)
Q2 2025	$79.18M	−$22.19M	−$19.58M	−$0.35	65.4%	-28.0%	−$17.85M	10-Q · 7 Aug 2025 (opens in a new tab)
Q1 2025	$69.16M	−$27.44M	−$24.74M	−$0.45	63.9%	-39.7%	−$18.82M	10-Q · 2 May 2025 (opens in a new tab)

Quarter ended	Reported	EPS	Consensus	Surprise
Jun 2026	8/4/2026	−$0.47	−$0.46	-2.2%
Mar 2026	4/29/2026	−$0.56	−$0.55	-1.8%
Dec 2025	2/25/2026	−$0.53	−$0.32	-65.6%
Sep 2025	11/4/2025	−$0.38	−$0.41	+7.3%

Cash and equivalents: $227.91M
Total assets: $479.35M
Total liabilities: $139.28M
Shareholders' equity: $340.07M
Long-term debt: $51.72M
Debt due within a year: $0

8-K · 3 Oct 2026 · Management change

PROCEPT BioRobotics Corporation reported A director or senior management change or compensation event (opens in a new tab)

PROCEPT BioRobotics Corporation filed an 8-K covering a director or senior management change or compensation event, supporting financial statements or exhibits.
8-K · 25 Sep 2026 · Material agreement Signed

PROCEPT BioRobotics Corporation reported A material agreement (opens in a new tab)

PROCEPT BioRobotics Corporation filed an 8-K covering a material agreement, supporting financial statements or exhibits.
10-Q · 6 Aug 2026

PROCEPT BioRobotics Corporation filed Form 10-Q (opens in a new tab)

PROCEPT BioRobotics Corporation submitted Form 10-Q to the SEC for the period ending Jun 30, 2026.
8-K · 5 Aug 2026

PROCEPT BioRobotics Corporation reported Operating or financial results (opens in a new tab)

PROCEPT BioRobotics Corporation filed an 8-K covering operating or financial results, supporting financial statements or exhibits.
SCHEDULE 13G/A · 29 Jul 2026

Large-holder ownership filing (opens in a new tab)

A holder reported or amended a beneficial ownership position of more than 5% in PROCEPT BioRobotics Corporation.

Insider	Date	Transaction	Shares	Average price	Filing
Mack Michael Director	2 Oct 2026	Grant or award (A)	+7,727	—	Form 4 (opens in a new tab)
Nouri Alaleh EVP, CLO, CORP. SEC.	9 Sep 2026	Open-market sale (S)	−297	$20.95	Form 4 (opens in a new tab)
Templin Barry L EVP, Chief Technology Officer	9 Sep 2026	Open-market sale (S)	−373	$20.95	Form 4 (opens in a new tab)
Waters Kevin EVP, CFO	9 Sep 2026	Open-market sale (S)	−373	$20.95	Form 4 (opens in a new tab)
Nouri Alaleh EVP, CLO, CORP. SEC.	13 Aug 2026	Grant or award (A)	+22,965	—	Form 4 (opens in a new tab)
Templin Barry L EVP, Chief Technology Officer	13 Aug 2026	Grant or award (A)	+26,246	—	Form 4 (opens in a new tab)
Waters Kevin EVP, CFO	13 Aug 2026	Grant or award (A)	+29,527	—	Form 4 (opens in a new tab)
Sharma Pooja Chief Strat/Marketing Officer	13 Aug 2026	Grant or award (A)	+23,622	—	Form 4 (opens in a new tab)

Institution	Report date	Shares	Change
Vanguard Group Inc	12/31/2025	5,202,306	-0.06%
Blackrock, Inc.	6/30/2026	4,869,828	11.642%
T. Rowe Price Investment Management, Inc.	6/30/2026	3,265,704	-0.247%
Bnp Paribas Asset Management Holding S.A.	6/30/2026	2,823,849	-8.595%
Vanguard Portfolio Management Llc	6/30/2026	2,526,802	4.355%
Vanguard Capital Management Llc	6/30/2026	2,460,802	2.573%
State Street Corp	6/30/2026	1,617,475	5.743%
Geode Capital Management, Llc	6/30/2026	1,484,163	8.85%
Fmr Llc	6/30/2026	1,444,878	-1.165%
Price T Rowe Associates Inc /Md/	6/30/2026	1,332,452	119.892%

Previous close: 18.82 USD
Day range: 18.15 – 18.98 USD
52-week range: 16.67 – 38.11 USD
Volume: 733,160
Market cap: $1.05B
Average volume: 1,209,951
EPS (FY 2025, diluted): −1.72 USD
Shares outstanding: 57.27M
Beta (5Y monthly): 0.85

Price, ranges and volume: Yahoo Finance (opens in a new tab) Observed 21 Oct 2026, 20:00 UTC· 11 hours ago

Average volume, P/E and shares: Nasdaq (opens in a new tab) Observed 22 Oct 2026, 06:32 UTC· 1 hour ago

EPS: SEC EDGAR company facts (opens in a new tab)

Beta: 5 years of monthly returns against the S&P 500, calculated from Yahoo Finance prices. Market cap is the price × shares outstanding.

This research is not available for PRCT yet

Guidance history

IMPORTANT FINANCIAL DISCLAIMER: The information provided on this platform is for educational and informational purposes only and should not be construed as investment advice. All investments involve risk, including potential loss of principal. Past performance does not guarantee future results. Take Profits is not a registered investment advisor and does not provide personalized investment advice. Users should conduct their own research and consult with qualified financial professionals before making investment decisions. Market data may be delayed and is provided by third-party sources.